SCHEMBL6318645

SCHEMBL6318645

Cc1[nH]c2ccc(C(=O)NS(=O)(=O)c3ccc(Cl)s3)cc2c1Cc1ccc(-c2ccccc2)cc1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.45
PTGS2 P35354 1/20 0.40
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
GAA P10253 1/20 0.38
TP53 P04637 2/20 0.37
LMNA P02545 3/20 0.37
GALR3 O60755 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MCL1 Q07820 5/20 0.36
POLB P06746 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
HTT P42858 1/20 0.36
RECQL P46063 1/20 0.36
MCOLN3 Q8TDD5 1/20 0.36
SCN9A Q15858 1/20 0.36
PTPN5 P54829 1/20 0.35
BCL2L1 Q07817 4/20 0.35
P2RY12 Q9H244 1/20 0.35
HDAC3 O15379 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6318323 0.92 MAPT (0.43) MAPTPTGS2TP53MCL1POLB
SCHEMBL6319584 0.89 MAPT (0.42) MAPTPTGS2MEN1KMT2AGAA
SCHEMBL5881622 0.88 MAPT (0.46) MAPTPTGS2MCL1BCL2L1HDAC3
SCHEMBL5882187 0.88 MAPT (0.41) MAPTPTGS2MEN1KMT2AGAA
SCHEMBL5881759 0.86 PTGS2 (0.46) MAPTPTGS2MCL1BCL2L1HDAC3
SCHEMBL6319329 0.85 PPARG (0.42) MAPTPTGS2MEN1KMT2AGAA
SCHEMBL5881771 0.83 FLT1 (0.51) MAPTPTGS2MCL1BCL2L1HDAC3
SCHEMBL6321446 0.83 MAPT (0.40) MAPTPTGS2MEN1KMT2AGAA
SCHEMBL5881987 0.83 MAPT (0.42) MAPTPTGS2KMT2ATP53MCL1
SCHEMBL5881720 0.83 PTGS2 (0.42) MAPTPTGS2MCL1BCL2L1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050171185-A1 Indole derivatives FUJISAWA PHARMACEUTICAL CO., LTD., A JAPANESE CORPORATION 2005-08-04 US claimed
EP-1070705-A1 INDOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-01-24 EP claimed
US-20050171185-A1 Indole derivatives FUJISAWA PHARMACEUTICAL CO., LTD., A JAPANESE CORPORATION 2005-08-04 US disclosed
EP-1070705-A1 INDOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-01-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171185-A1 Indole derivatives PDE5A, IGFBP5, HTR5A MAPT 3941/4885PTGS2 2111/4885MEN1 3818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.